Physician profile
Aman Jafar
NPI 1912999426
$1,702.40
in general payments reported to CMS, 2019-2025
23 companies · $52.27 in 2025
The $52.27 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $73.57 · 2021: $154 · 2022: $338 · 2023: $879 · 2024: $79.07 · 2025: $52.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854 · Travel and Lodging: $141 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.71 |
| Travel and Lodging | $140.66 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $453.46 | 2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $399.70 | 2020-2023 | Farxiga |
| Sunovion Pharmaceuticals INC. | $199.09 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.42 | 2023 | Lifevest |
| Alafair Biosciences, INC. | $79.25 | 2023 | Versawrap |
| Lilly USA, LLC | $54.68 | 2022-2023 | Mounjaro |
| Abbott Laboratories | $46.36 | 2023 | Eterna |
| Glaxosmithkline, LLC. | $42.10 | 2024 | Arexvy, Trelegy Ellipta |
| Ucb, INC. | $35.85 | 2021 | |
| Sumitomo Pharma America, INC. | $31.33 | 2023 | Aptiom, Gemtesa |
| Medtronic, INC. | $27.74 | 2025 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $24.53 | 2025 | Austedo Xr |
| Astellas Pharma US INC | $24.22 | 2019 | |
| Hikma Pharmaceuticals USA | $23.45 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.79 | 2024 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.16 | 2020 | |
| Nestle Healthcare Nutrition INC. | $21.33 | 2022 | |
| Avanir Pharmaceuticals, INC. | $20.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.82 | 2019 | |
| Lundbeck LLC | $16.95 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.09 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.18 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Jafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.